2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.22 Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study

EP.12A.22 Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study

Back to course

Pdf Summary

The study conducted by J. Xu and colleagues at The First Affiliated Hospital of Nanjing Medical University investigates the efficacy and safety of combining aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor, with platinum-based chemotherapy as a first-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The study is inspired by the positive results from the FLAURA2 study, which showed that combining first-line osimertinib with chemotherapy improved progression-free survival (PFS) compared to osimertinib alone.<br /><br />The real-world study enrolled 94 patients with advanced EGFR-mutant NSCLC who had not received prior treatment. Patients were treated with aumolertinib and platinum-pemetrexed chemotherapy, followed by maintenance with pemetrexed and aumolertinib. Key endpoints assessed were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.<br /><br />Results showed a median PFS of 30.5 months, with the OS not yet reached, and 1-, 2-, and 3-year OS rates of 100%, 84%, and 76.9%, respectively. The ORR was 78%, and DCR was 100%. Patients with the 19 deletion mutation had a significantly longer PFS compared to those with the L858R mutation. Furthermore, PFS was notably higher in patients without central nervous system metastasis.<br /><br />In terms of safety, 90.4% of patients experienced all-grade adverse events, with 34% experiencing Grade 3 events, primarily neutropenia and thrombocytopenia. Only 3.2% discontinued treatment due to side effects.<br /><br />The study concludes that aumolertinib combined with chemotherapy is a promising first-line treatment option for EGFR-mutated advanced NSCLC, offering a strong efficacy and safety profile, potentially better than the results seen in the FLAURA2 study.

Asset Subtitle

Jiali Xu

Meta Tag

Speaker Jiali Xu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

aumolertinib

EGFR-mutated

NSCLC

first-line treatment

chemotherapy

progression-free survival

overall survival

adverse events

FLAURA2 study

real-world study